Aurigene Announces First in Human Dosing with RoRγt inverse agonist AUR-101

– Phase 1 data from the study expected to be available by December 2018   Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders,

Aurigene and its Partner Curis Announce the dosing of CA-170 in Phase II India trial

The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial. Aurigene Discovery Technologies Limited, a wholly owned subsidiary

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017 — Results from 34 patients demonstrate positive safety profile and

Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target

CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism

Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation (WCI), 2015

BOSTON, August 5, 2015 /PRNewswire/- Aurigene will be presenting data at the poster session for its proprietary RAR-related orphan receptor gamma (RORγ) small molecule inverse agonists program, which is currently in preclinical

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

LEXINGTON, Mass. and Bangalore, India, January 21, 2015 (GLOBENEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of

Aurigene and Orion Corporation Announce Research, Collaboration and Option Agreement for Rights to Aurigene’s Epigenetics Program for Pan BET and Selective BET Bromodomain Inhibitors

ESPOO, Finland and BANGALORE, India, June 24, 2014 /PRNewswire/ — Orion Corporation, a globally operating Finnish pharmaceuticals company and Aurigene, a leading biotech company based in India, today announced that